Abstract
A stability-indicating high-performance liquid chromatographic method was developed and validated for the determination of orbifloxacin in tablet dosage forms. Reversed-phase chromatography was performed on a Symmetry Shield RP-18 Waters®, 250mm×4.6mm i.d., 5 μm particle size column with 5% acetic acid:methanol (80:20, v/v) as mobile phase at a flow rate of 0.7 ml/min. PDA detection was performed at 290 nm. A well resolved peak was obtained for orbifloxacin at a retention time of approximately 7.9 min. For stress studies the drug was subjected to oxidation, hydrolysis, photolysis and thermal degradation. The developed method was validated as per ICH guidelines for the parameters such as system suitability, linearity, limit of quantification (LOQ), limit of detection (LOD), precision, accuracy, selectivity and robustness. Results obtained were found to be satisfactory. No interference from any excipients in the pharmaceutical dosage form or degradation products was observed.
Keywords: Degradation products, HPLC-UV, Liquid chromatography, Orbifloxacin, Stability-indicating method, Validation, Limit of quantification, Limit of detection, Stress studies, Oxidation, Hydrolysis, Photolysis, Thermal degradation
Related Journals
Related Books
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Biologically Active Natural Products from Asia and Africa: A Selection of Topics
7